Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS) Device
-- Agreement extends existing partnership --
-- Collaboration makes HealthTech Connex the exclusive provider of PoNS Therapy in the Vancouver area and will greatly strengthen Helius’s presence in the region --
NEWTOWN, Pa., March 22, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, and HealthTech Connex Inc. (“HTC”), a leading health technology company specializing in neurotechnology innovations, announced today that they have entered into an exclusive distribution agreement.
This agreement, which replaces Helius and HTC’s prior clinical research and co-promotion agreement, grants HTC the exclusive right to purchase, market, sell, and distribute Helius’s PoNS device throughout the metropolitan Vancouver and Fraser Valley regions of British Columbia, Canada, subject to established minimums. The initial term is for five years, with the possibility to extend to ten years.
“HTC has been an important partner for Helius and we are delighted to extend this valuable collaboration. PoNS is the perfect fit for HTC’s leading-edge neurorehabilitation clinics and this agreement will allow Helius to establish a strong presence in the greater Vancouver area while continuing to help HTC empower patients who suffer from gait and balance impairment improve their daily lives,” said Helius President and Chief Executive Officer Dane Andreeff.
“We’re thrilled to announce the collaboration with Helius that gives HTC exclusive rights to purchase, market, sell, and distribute Helius’s PoNS device throughout the metropolitan Vancouver and Fraser Valley regions of British Columbia. This will allow HTC to continue providing groundbreaking treatment using the PoNS device to make a positive impact in the lives of countless people in British Columbia,” stated Kirk Fisher, Chief Executive Officer of HTC.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS) device. For more information about the PoNS or Helius Medical Technologies, visit www.heliusmedical.com.